
Increase in intraocular pressure found to be tolerable to the corneal endothelium and safe for treating central serous chorioretinopathy or diabetic macular edema.

Increase in intraocular pressure found to be tolerable to the corneal endothelium and safe for treating central serous chorioretinopathy or diabetic macular edema.

Increased virologic failure and drug resistance following dolutegravir monotherapy prompt researchers to recommend against its use in patients with HIV.

Advances in technology can guide insulin regimens prescribed at discharge among patients with diabetes.

Published: November 28th 2017 | Updated:

Published: November 27th 2017 | Updated:

Published: February 12th 2018 | Updated: